Keep up to date with the latest news from Bayer’s businesses in Romania and worldwide. Please note that some headline links may take you to other Bayer websites outside Romania. Medical information, including licensed uses and availability, may be different outside the region.
If you are looking for older headlines please get in touch at email@example.com
Bayer aduce în România un tratament ce poate deveni noul standard terapeutic pentru pacienţii cu ateroscleroză şi risc cardiovascular crescut
Bayer closes Monsanto acquisition
Leverkusen, June 7, 2018– Bayer successfully completed the acquisition of Monsanto on Thursday. Shares in the U.S. company will no longer be traded on the New York Stock Exchange, with Bayer now the sole owner of Monsanto Company. Monsanto shareholders are being paid 128 U.S. dollars per share. J.P. Morgan assisted Bayer with processing the purchase price payment for the largest acquisition in the company’s history. According to the conditional approval from the United States Department of Justice, the integration of Monsanto into Bayer can take place as soon as the divestments to BASF have been completed. This integration process is expected to commence in approximately two months. more
Bayer plans closing of Monsanto acquisition on June 7
Largest acquisition in company history to double size of agriculture business / Leading innovation engine in agriculture with pro forma R&D investment of 2.4 billion euros in 2017 / Transaction anticipated to generate significant value / Bayer strengthens commitment to sustainability and stakeholder engagement / Bayer to remain company name more
Bayer: Operational business held back by currency effects – Major progress with Monsanto acquisition
Group sales increase by 2.0 percent (Fx & portfolio adj.) to 9.138 billion euros / EBITDA before special items down year on year at 2.896 billion euros due to currency effects – level with prior-year quarter on a currency-adjusted basis / Sales increase at Pharmaceuticals (Fx & portfolio adj.) / Consumer Health down year on year, as expected / Sales of Crop Science match strong prior-year quarter (Fx & portfolio adj.) / Animal Health raises sales (Fx & portfolio adj.) and earnings / Net income declines by 6.2 percent to 1.954 billion euros / Core earnings per share down 1.3 percent at 2.28 euros / European Commission and additional regulators conditionally approve Monsanto acquisition / Currency adjusted Group outlook for 2018 confirmed more
Neonicotinoid Ban: a Sad Day for Farmers and a Bad Deal for Europe
Monheim, April 27, 2018 – Today's decision by the EU Member States to restrict the use of certain neonicotinoids to applications in permanent greenhouses is a bad deal for the European agricultural sector and the environment, and one that will not improve the lot of bees or other pollinators. The decision will further reduce European farmers' ability to tackle important pests, for many of which there are no alternative treatments available. more
Monheim, April 27, 2018 – Today's decision by the EU Member States to restrict the use of certain neonicotinoids to applications in permanent greenhouses is a bad deal for the European agricultural sector and the environment, and one that will not improve the lot of bees or other pollinators. The decision will further reduce European farmers' ability to tackle important pests, for many of which there are no alternative treatments available.